Your Biopharmaceutical Development and Manufacturing Partner

Board of Directors

The present Board of Directors for Nanotherapeutics comprises extensive experience in the areas of business and financial operations, strategy, development and commercialization. The profiles are provided as follows:


Weaver H. Gaines, Chairman of the Board

In addition to being Chairman, Mr. Gaines was also General Counsel of the Company until February 2014, when he resigned as General Counsel to serve as President and CEO of OBMedical Company, a medical device company offering LaborView(R), a wireless maternal-fetal monitoring electrode system.  Prior to joining the Company in 2008, Mr. Gaines was a founder and Managing Director of Americas Biotech Distributor LLC (Latin American distribution of US products). Before founding ABD, Mr. Gaines was a co-founder of Ixion Biotechnology, Inc. where he served as Chairman and CEO until 2007. Prior to that, Mr. Gaines was a Senior Adviser on the Bush/Quayle 92 national campaign staff. From 1985 to 1992, he held various executive positions with The Mutual Life Insurance Company of New York, including Executive Vice President responsible for law, external affairs, and certain non-insurance operating subsidiaries. Previously he was vice president for corporate development of Indian Head, Inc., a multi-billion dollar, privately-held, industrial product manufacturing company and before that a Senior Staff Counsel at the Insurance Company of North America. He began his professional career at the Wall Street law firm of Dewey Ballantine.

Mr. Gaines is also a co-founding director of the Florida Research Consortium and is a co-founder, director emeritus, and Chairman emeritus of BioFlorida, the Florida biomedical trade association. He is a member of the Industry Advisory Council of the Keck Graduate Institute of Applied Life Sciences and a Trustee of the Torrey Pines Institute for Molecular Studies.


Ronald R. Blanck, D.O., Lieutenant General, US Army, Retired

Lieutenant General Ronald R. Blanck, DO, U.S. Army, Retired, is a partner and Chairman of the Board of Martin, Blanck & Associates. The company does health care consulting for the private sector and the government. He retired as the President of the University of North Texas Health Science Center at Fort Worth June 30, 2006. As president, Dr. Blanck headed an academic health center that includes the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health and School of Health Professions.  He is a graduate of the Philadelphia College of Osteopathic Medicine and  is board certified in internal medicine. He joined the UNT Health Science Center in August 2000 after his retirement from the U.S. Army.

Dr. Blanck began his military career in 1968 as a medical officer and battalion surgeon in Vietnam. He retired 32 years later as the Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command - with more than 46,000 military personnel and 26,000 civilian employees throughout the world. 

During his distinguished military career, Dr. Blanck also served as commander of Walter Reed Medical Center, North Atlantic Region Medical Command and Director of Professional Services and Chief of Medical Corps Affairs for the U.S. Army Surgeon General. Other assignments included Assistant Dean of Student Affairs at the Uniformed Services University School of Medicine, Chief of the Department of Medicine at Brooke Army Medical Center, Commander, Berlin Army Hospital and Commander, Frankfurt Regional Army Medical Center.


Marily Rhudy                                  

Marily H. Rhudy brings 30 years of experience in the pharmaceutical and health care industry having served as Senior Vice President for Global Public Affairs at then-Wyeth for 13 years. She has held roles in leading healthcare policy organizations and is former President and Chair of the American Pharmaceutical Association in Washington, DC and organization she served for over 10 years.  Ms. Rhudy served on The White House Task Force on Health Care Reform in 1993 having been appointed by President Clinton as the pharmacist representative to the Health Care Professions Review Group in. 

She has held leadership positions in the pharmaceutical industry, culminating in a career leading complex public policy initiatives at the local, state, federal and international level.  Ms. Rhudy led the Public Affairs Department at then-Wyeth where she was responsible for a team of 100 professionals. Her remit included the Company’s three divisions – consumer health, pharmaceuticals and animal health.  While at Wyeth she served on the Company’s Management and Operations Committee and reported to the Chairman and CEO.

After retirement from Wyeth in 2008 she launched a Washington-based consulting practice and has since aided several companies in establishing or improving their public policy and government affairs functions. Ms. Rhudy is a graduate of the University Of Kansas School Of Pharmacy where she was awarded Distinguished Alumnae status in 1998.  In 2014 she was inducted into the Kansas University Women’s Hall of Fame.


William H. Washecka

William H. Washecka became a Director in 2014 and has  served on the boards of a number of  public companies.  He was  Chief Financial Officer of Prestwick Pharmaceuticals, which specialized in therapies for central nervous system disorders and which was acquired by Biovale Corporation in 2008.  From 2001- 2002, Mr. Washecka served as Senior Executive Vice President and Chief Financial Officer for USinternetworking, Inc., an enterprise and e-commerce software service provider. Mr. Washecka was a Senior Partner and Director of High Technology at Ernst & Young LLP until 2001. During nearly 30 years at Ernst & Young,Mr Washecka assisted hundreds of  companies through various stages of growth. His responsibilities included auditing, business and strategic planning, financing strategies and assistance with mergers and acquisitions. Some of the high technology companies with which Mr. Washecka has worked include Human Genome Sciences, Digene Diagnostics, Martek Biosciences,  Apple Computer, and America Online (AOL). During the past five years, Mr. Washecka served on the board of Authentech, Inc., which was acquired by Apple Computer and where he was the Chairman of the Board and audit committee chair. Previously, he also served on the board of Audible, Inc. which was acquired by Amazon in 2008. He has a B.S. in accounting from Bernard Baruch College of New York and completed the Kellogg Executive Management Program. Mr. Washecka's decades of experience in auditing and accounting will enhance our internal controls over financial reporting, and  the quality of our public financial disclosures. 


Alan D. Wheat, Chair, Public Policy, Polsinelli

With 18 years of experience as an elected official, and chair of Polsinelli's Public Policy practice, the Honorable Alan Wheat, remains a highly regarded figure in Washington among his peers and former colleagues, many of whom now occupy Washington’s most senior leadership positions both on Capitol Hill and within the Administration. Recognized in Congress for his extraordinary skill in building coalitions, Congressman Wheat continues to garner support for important client concerns and initiatives in his role as Chairman for Polsinell’s Public Policy practice. 

In 1982 he was elected to the United States House of Representatives, where he became part of the House leadership as the youngest member in Congressional history to be appointed to the powerful Rules Committee. While in Congress, he was one of the nation's first African-Americans to represent a district with a white majority. He proved his skills as a strong political leader serving as Chief Deputy Whip and in 1994 he ran for a seat in the United States Senate. He further made history by becoming the first minority candidate selected as a major party nominee for statewide office in Missouri. 

Following his Senate race, Congressman Wheat became Vice President of Public Policy and Government Relations with one of the largest and most vital global relief and development organizations, CARE. In 1996, he was named deputy campaign manager and director of public liaison for Clinton-Gore '96. During this period he developed and executed plans that mobilized more than twenty essential constituency groups to support President Clinton’s re-election. In addition, he traveled across the country as a spokesperson for the president and vice president. His work has allowed him to develop an extensive and bipartisan network of contacts in Washington. 

Congressman Wheat counts many of Washington’s most influential voices among his relationships. Those relationships are at the highest levels of Executive Agencies, the White House, House and Senate leadership, the key committees in both the House and Senate and numerous advocacy organizations.


James M. Matthew,  Chief Financial Officer

Mr. Matthew joined the Nanotherapeutics Board of Directors in February 2008 and became the Chief Financial Officer of the Company in March 2011. Mr. Matthew is a member of the Board of Managers of NANO ADM, LLC, a wholly-owned subsidiary of the Company.   He became  President and Chief Executive Officer in May 2016.  Mr. Matthew has over 30 years of financial experience, including more than 10 years as the Chief Financial Officer of public and private companies with responsibilities for accounting, finance, information management, investor relations, procurement and facility services.  In addition, he has 20 years of experience with KPMG where he was responsible for a variety of transactions and financings for the Health Care and Life Sciences Industry Group.  Mr. Matthew received an MBA from Michigan State University and a B.S. in Accountancy from the University of Illinois at Springfield.


Prasad S Raje, Ph.D.,  President and Chief Executive Officer

Dr. Raje was appointed CEO and Member of the Board of Directors of Nanotherapeutics in November 2016. Dr. Raje comes to the company with over 20 years of experience as a recognized global leader with deep experience forging business alliances that help companies increase sales and revenue growth through market expansion. Prior to joining Nanotherapeutics, Dr. Raje was Senior Vice President and Head of the Life Sciences Division of EAG Laboratories, a Contract Research Organization serving, among other sectors, pharmaceutical drug development. Prior to EAG, Dr. Raje was a business owner, the President and Managing Director, AMRI India PVT. LTD – Mumbai, India and held executive positions with several CRO/CMO companies where his excellent short and long term strategic planning abilities and operational expertise repeatedly produced revenue and EBITDA growth in dynamic and changing markets. Dr. Raje received his undergraduate degree and Master of Science degree from Gujarat University, Gujarat India and his Ph.D. from Auburn University, Auburn Alabama. Dr. Raje’s academic credentials include 9 patents and 16 peer-reviewed published papers.


Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.